News

Company brings aboard former Pfizer exec as life sciences COO in effort to help further improve patient outcomes.

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Project to focus on improving access to EstroGel.

Deal to focus on development and commercialization in key emerging countries.

Deal aims to provide diabetes treatment to patients across the continent.

Nearly 96% of respondents say that this is an issue affecting their respective pharmacy.

Expansion is expected to meet the growing market demand from the region.

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.

The program to facilitate engagement between HCPs, industry, and regulatory bodies.

SaaS’ branded platform expected to help grow manufacturer’s therapeutic development processes.

CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.

The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.

PBM transparency and data reporting requirements are likely to be part of a larger healthcare bill that Congress will work on this fall.

Protective case manufacturer hires James Curleigh, as company prepares to further innovation and expand.

Appointment comes amid resignation of Marie-France Tschudin from company executive committee.

Collaboration aims to expedite the transportation of cancer detection radiopharmaceuticals throughout Chile.

Financial commitment is intended to benefit development and commercialization of new products.

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

Organization hires Kala Shankle, who joins the team with supply chain security and drug pricing experience.

IATA statistics suggest improvement over recent months.

Novo Nordisk receives the full rights to develop and commercialize the lead program.

Pharma Commerce provides a synopsis of the presentation.

Biopharma company now required to seek approval before attempting further buyouts.

Shift comes with $5 million dedication to launch Cencora’s healthier futures grant program.

Alexion – AstraZeneca Rare Disease, GSK, Novartis, Pfrizer, and Zoetis will join the newly established life sciences platform.

Delay to allow agency to consider other ways of solving the issue, filing says.

The latest people news happenings over the past month.

Collaboration to focus on digital therapeutics.